Advances of Treatment of Pulmonary Large Cell Neuroendocrine Carcinoma

TL;DR

This paper reviews the treatment of a rare and aggressive lung cancer called large cell neuroendocrine carcinoma, focusing on new insights from molecular subtypes and immune checkpoint inhibitors.

Contribution

The paper provides a comprehensive overview of recent advances in molecular subtyping and immunotherapy for LCNEC.

Findings

Molecular subtyping using next-generation sequencing helps guide treatment decisions for LCNEC.

Immune checkpoint inhibitors show promise but are based on limited retrospective studies and case reports.

Current treatment strategies for LCNEC are largely borrowed from small and non-small cell lung cancer.

Abstract

肺大细胞神经内分泌癌（large cell neuroendocrine carcinoma, LCNEC）是一种罕见且高度侵袭性的高级别神经内分泌癌，患者确诊时分期偏晚，预后差，其治疗策略多借鉴小细胞肺癌和非小细胞肺癌的方案。近年来，二代测序技术为LCNEC的精准分型提供了理论基础，研究也证实了不同LCNEC亚型与化疗方案疗效之间的关联性。免疫检查点抑制剂（immune checkpoint inhibitors, ICIs）的应用，为LCNEC患者提供了新的治疗选择，但相关数据仅见于小样本的回顾性研究和少量个案报道。本文回顾了LCNEC的流行病学特征和经典治疗策略，并针对LCNEC的分子亚型研究进展和ICIs的应用进展进行综述，为临床治疗提供新思路。

Summary of available studies on ICIs in LCNEC